EAST update 9/787,426

L Number	Hits	Search Text	DB	Time stamp
1	2057	((514/269) or (514/275)).CCLS.	USPAT; US-PGPUB	2004/05/27 09:35
2	2129	((544/297) or (544/298) or (544/319) or (544/320)).CCLS.	USPAT; US-PGPUB	2004/05/27 09:37
3	3642	(((514/269) or (514/275)).CCLS.) or (((544/297) or (544/298) or (544/319) or (544/320)).CCLS.)	USPAT; US-PGPUB	2004/05/27 09:37
4	1090	((((514/269) or (514/275)).CCLS.) or (((544/297) or (544/298) or (544/319) or (544/320)).CCLS.)) and (pyrimidin or pyrimidinone or pyrimidone)	USPAT; US-PGPUB	2004/05/27 09:38
5	685	(((((514/269) or (514/275)).CCLS.) or (((544/297) or (544/298) or (544/319) or (544/320)).CCLS.)) and (pyrimidin or pyrimidinone or pyrimidone)) and (pyridinyl or pyridyl)	USPAT; US-PGPUB	2004/05/27 09:39
6	672	((((((514/269) or (514/275)).CCLS.) or (((544/297) or (544/298) or (544/319) or (544/320)).CCLS.)) and (pyrimidin or pyrimidinone or pyrimidone)) and (pyridinyl or pyridyl)) not '2-oxo'	USPAT; US-PGPUB	2004/05/27 09:39
7	619	(((((((514/269) or (514/275)).CCLS.) or (((544/297) or (544/298) or (544/319) or (544/320)).CCLS.)) and (pyrimidin or pyrimidinone or pyrimidone)) and (pyridinyl or pyridyl)) not '2-oxo') not uracil	USPAT; US-PGPUB	2004/05/27 09:39

09/ 787,426

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12	APR 26	PROMT: New display field available
NEWS 13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 14	APR 26	LITALERT now available on STN
NEWS 15	APR 27	NLDB: New search and display fields available
NEWS 16	May 10	PROUSDDR now available on STN
NEWS 17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS 18	May 12	EXTEND option available in structure searching
NEWS 19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 20	May 17	FRFULL now available on STN
NEWS 21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS 22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 23	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 24	May 27	Explore APOLLIT with free connect time in June 2004

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

FILE 'HOME' ENTERED AT 14:14:26 ON 27 MAY 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:14:35 ON 27 MAY 2004

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2004 HIGHEST RN 686262-86-2
DICTIONARY FILE UPDATES: 26 MAY 2004 HIGHEST RN 686262-86-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\09787426.str

chain nodes :
7 8 15
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
chain bonds :
1-15 2-7 4-9 6-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
1-2 1-6 1-15 2-3 2-7 3-4 4-5 5-6 6-8

exact bonds :
4-9
normalized bonds :
9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 14:14:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1614 TO ITERATE

100.0% PROCESSED 1614 ITERATIONS 161 ANSWERS
SEARCH TIME: 00.00.01

L2 161 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 155.42 155.63

FILE 'CAPLUS' ENTERED AT 14:15:03 ON 27 MAY 2004

09/ 787,426

FILE COVERS 1907 - 27 May 2004 VOL 140 ISS 22
FILE LAST UPDATED: 26 May 2004 (20040526/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 20 L2

=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 20 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:1006976 CAPLUS
DOCUMENT NUMBER: 140:59653
TITLE: Preparation of phenylaminopyrimidines as rho-kinase inhibitors
INVENTOR(S): Feurer, Achim; Bennabi, Samir; Heckroth, Heike; Ergueden, Jens; Schenke, Thomas; Bauser, Markus; Kast, Raimund; Stasch, Johannes-Peter; Stahl, Elke; Muenter, Klaus; Lang, Dieter; Ehmke, Heimo
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106450	A1	20031224	WO 2003-EP5827	20030604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10226943	A1	20040108	DE 2002-10226943	20020617

PRIORITY APPLN. INFO.: DE 2002-10226943 A 20020617
OTHER SOURCE(S): MARPAT 140:59653
GI



I



AB Title compds. [I; R1 = amino, OH; R2 = H, alkyl, cycloalkyl; R3, R4 = cyano, H, F, Cl; A = Q1-Q3; R5, R6 = H, F, Cl; D = (substituted) Ph, (iso)quinoline, indole, etc.], were prepared for treating cardiovascular diseases. Thus, 4-chloro-6-quinolin-6-yl-pyrimidin-2-amine (preparation given) and 3-fluoro-4-(4-pyridinylsulfanyl)aniline (preparation given) were treated with 37% HCl followed by stirring for over night at 100° to give 12% N-[2-amino-6-(6-quinolinyl)-4-pyrimidinyl]-N-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]amine. The latter inhibited Rho-kinase II (ROKα) with IC50 = 7 nM.

IT **54950-12-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylaminopyrimidines as rho-kinase inhibitors)

RN 54950-12-8 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:591171 CAPLUS

DOCUMENT NUMBER: 139:149645

TITLE: Preparation of pyrimidine derivatives for use in pharmaceutical compositions as Rho-kinase inhibitors

INVENTOR(S): Nagarathnam, Dhanapalan; Dumas, Jacques;

09/ 787,426

Hatoum-Mokdad, Holia; Boyer, Stephen; Pluempe, Hans
PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062227	A1	20030731	WO 2003-US1840	20030123
US 2004002507	A1	20040101	US 2003-349176	20030123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-349986P P 20020123

GI



I



II

AB Pyrimidine derivs., such as I [R = H, Ph; R1 = H, alkyl, aryl, heteroaryl, halogen; R2 = H, alkyl, halogen; R1R2 = (CH2)3-5; R3 = heteroaryl, such as pyridinyl, quinolinyl or isoquinolinyl; X = O, S; R4, R5 = H, Cl, F], were prepared for therapeutic use as Rho-kinase inhibitors. These pyrimidine derivs. are useful for inhibiting tumor growth in cancer of the breast, colon, prostate, ovaries, brain or lung, and for treatment of other disorders mediated by Rho-kinase, such as erectile dysfunction, coronary heart disease, hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neuronal degeneration, spinal cord injury, asthma, glaucoma and osteoporosis. Thus, II was prepared in 18% yield by reacting 2-amino-4-chloro-6-methylpyrimidine with 3-fluoro-4-(4-pyridinylthio)aniline using K2CO3 in o-xylene at 100° overnight. The prepared pyrimidine derivs. were assayed for inhibition of ROCK-I phosphorylation of myelin basic protein.

IT **54950-12-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. for use in pharmaceutical compns. as Rho-kinase inhibitors)

RN 54950-12-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:591169 CAPLUS
DOCUMENT NUMBER: 139:149643
TITLE: Preparation of pyrimidinamines as Rho-kinase inhibitors for inhibiting tumor growth, treating erectile dysfunction, and other therapeutic uses
INVENTOR(S): Nagarathnam, Dhanapalan; Dumas, Jacques; Hatoum-mokdad, Holia; Boyer, Stephen; Wang, Chunguang; Pluempe, Hans; Feurer, Achim; Bennabi, Samir
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062225	A1	20030731	WO 2003-US1839	20030123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004002508	A1	20040101	US 2003-349177	20030123

PRIORITY APPLN. INFO.: US 2002-349987P P 20020123
OTHER SOURCE(S): MARPAT 139:149643
GI



I

AB Disclosed are pyrimidinamines (shown as I; variables defined below; e.g. 4-[[4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl]sulfanyl]phenol), their synthesis, and their use as Rho-kinase inhibitors (no data). These compds. are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. For I: R1 and R2 = H, halo, alkyl (un)substituted by halo up to perhalo, cycloalkyl, alkenyl, alkynyl, NO2, NH2, NR6R7, or furyl, thienyl, pyridyl, trifluoromethyl or Ph each (un)substituted with NH2, NO2 trifluoromethyl or alkoxy; or R1 and R2 may be taken together to form a ring of = 5-7 members optionally interrupted by N and (un)substituted on N by benzyl. R3 = NH2 or -NH- Ph (un)substituted with halo, C1-C4 alkyl, trifluoromethyl, nitro or amino; R4 = X-A- and R5n-substituted Ph, R5n-substituted 6-X-Apyridin-3-yl or indol-5-yl (un)substituted on N with pyridyl; X is a linker substituted at the 3 or 4 position of the ring and is O, S, -S-CH2-, -(CH2)m-, or -C(O)-; A is Ph (un)substituted with alkylthio or OH, pyridyl, quinolyl or isoquinolyl. Each R5 independently is halo, alkyl (un)substituted by halo up to perhalo, cycloalkyl, alkoxy, alkenyl, alkynyl, NO2, NH2, or trifluoromethyl; n is 0-4; m is 1 or 2; and R6 and R7 are each independently H, alkyl, cycloalkyl, or Ph (un)substituted with halo, CF3, alkyl, nitro or amino; or R6 and R7 may form, together with the N atom to which they are attached, a heterocyclic ring (un)substituted with alkyl, optionally interrupted by O, or optionally fused to phenyl; addnl. details including provisos are given in the claims. More than 30 example prepns. of I plus many prepns. of intermediates are included. For example, 4-[[4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl]mercapto]phenol (0.11 mmol, 51% yield) was prepared from 2-amino-4-chloro-6-ethylpyrimidine (0.23 mmol) and 4-[(4-aminophenyl)sulfanyl]phenol (0.25 mmol) suspended in a mixture of 0.01M aqueous HCl (230 μL) and 1-butanol (230 μL); the mixture was refluxed overnight.

IT **54950-12-8P**, 2-Amino-4-hydroxy-6-(4-pyridyl)pyrimidine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidinamines as Rho-kinase inhibitors for inhibiting tumor growth, treating erectile dysfunction, and other therapeutic uses)

RN 54950-12-8 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN

09/ 787,426

ACCESSION NUMBER: 2001:713340 CAPLUS
DOCUMENT NUMBER: 135:272981
TITLE: Preparation of 2-(arylalkylamino)pyrimidones and 2-(heteroarylalkylamino)pyrimidones for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β
INVENTOR(S): Almario Garcia, Antonio; Ando, Ryoichi; Aritomo, Keiichi; Frost, Jonathan Reid; Li, Adrien Tak; Shoda, Aya; Uehara, Fumiaki; Watanabe, Kazutoshi
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1136484	A1	20010926	EP 2000-400804	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1136099	A1	20010926	EP 2000-400805	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1136491	A1	20010926	EP 2000-400806	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001270884	A2	20011002	JP 2000-81938	20000323

PRIORITY APPLN. INFO.:
EP 2000-400804 A 20000323
EP 2000-400805 A 20000323
EP 2000-400806 A 20000323
JP 2000-81938 A 20000323

OTHER SOURCE(S): MARPAT 135:272981
GI



I

AB The title compds. [I; R2 = H, perhalogenated alkyl, (un)substituted alkyl; R3 = 2-, 3- or 4-pyridyl optionally substituted by alkyl, alkoxy or a halogen; and when n = 1-10, the R1 = unsubstituted naphth-1-yl, unsubstituted naphth-2-yl, aryl, etc.; when n = 4-10 then R1 can represent

in addition an unsubstituted Ph; and when n = 1-3 and R1 = unsubstituted Ph then R2 = perhalogenated alkyl or substituted alkyl] and their pharmaceutically acceptable salts which are used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3β, were prepared and formulated. The compds. I were synthesized by reacting Et 3-(4-pyridyl)-3-oxopropionate (preparation given) with R1(CH2)nNR2C(:NH)NH2 or by reacting 2-(methylthio)-6-(pyridin-4-yl)pyrimidin-4(1H)-one (preparation given) with R1(CH2)nNHR2. The compds. I such as I [R1 = 3,4-(MeO)2C6H3; R2 = H; R3 = 4-pyridyl] showed IC50's of 0.01-10 μM against GSK3β.

IT **361484-66-4P 361484-67-5P 361484-68-6P**
361542-10-1P 361542-11-2P 361542-12-3P
361542-13-4P 361542-14-5P 361542-15-6P
361542-16-7P 361542-17-8P 361542-18-9P
361542-19-0P 361542-20-3P 361542-21-4P
361542-22-5P 361542-23-6P 361542-24-7P
361542-25-8P 361542-26-9P 361542-27-0P
361542-28-1P 361542-29-2P 361542-30-5P
361542-31-6P 361542-32-7P 361542-33-8P
361542-34-9P 361542-35-0P 361542-36-1P
361542-37-2P 361542-38-3P 361542-39-4P
361542-40-7P 361542-41-8P 361542-42-9P
361542-43-0P 361542-44-1P 361542-45-2P
361542-46-3P 361542-47-4P 361542-48-5P
361542-49-6P 361542-50-9P 361542-51-0P
361542-52-1P 361542-54-3P 361542-55-4P
361542-56-5P 361542-57-6P 361542-58-7P
361542-59-8P 361542-60-1P 361542-61-2P
361542-62-3P 361542-63-4P 361542-64-5P
361542-65-6P 361542-66-7P 361542-67-8P
361542-68-9P 361542-69-0P 361542-70-3P
361542-71-4P 361542-72-5P 361542-73-6P
361542-75-8P 361542-76-9P 361542-77-0P
361542-78-1P 361542-79-2P 361542-80-5P
361542-82-7P 361542-84-9P 361542-85-0P
361542-86-1P 361542-87-2P 361542-89-4P
362048-04-2P 362048-06-4P 362048-07-5P
362048-08-6P 362048-09-7P 362048-10-0P
362048-12-2P 362048-13-3P 362048-14-4P
362601-30-7P 362601-35-2P 362601-36-3P
362601-37-4P 362601-38-5P 362601-39-6P
362601-41-0P 362601-42-1P 362601-43-2P
362601-44-3P 362601-45-4P 362601-47-6P
362601-49-8P 362601-50-1P 362601-51-2P
362601-52-3P 362601-54-5P 362601-55-6P
362601-56-7P 362601-58-9P 362601-59-0P
362601-60-3P 362601-61-4P 362601-62-5P
362601-64-7P 362601-65-8P 362601-67-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(arylalkylamino)pyrimidones and 2-(heteroarylalkylamino)pyrimidones for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β)

RN 361484-66-4 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(3-furanylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-67-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361484-68-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(2-thienyl)ethyl]amino]- (9CI)
(CA INDEX NAME)



RN 361542-10-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-11-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-12-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-13-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-14-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-15-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-16-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-17-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-18-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-bromophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-19-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,4-dichlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-20-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-21-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-22-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-nitrophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-23-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-aminophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-24-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-25-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-26-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-27-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methylphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-28-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 361542-29-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-30-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-phenylbutyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-31-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-[1,1'-biphenyl]-4-ylethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-32-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-naphthalenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-33-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-34-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-35-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methylphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-36-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-37-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-fluorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-38-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-39-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-40-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-41-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 361542-42-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-nitrophenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-43-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-aminophenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-44-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-45-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-46-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-47-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-48-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-49-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-aminophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-50-9 CAPLUS
CN Acetamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-
pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-51-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-
pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-52-1 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(2-pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-54-3 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-55-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-aminophenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-56-5 CAPLUS
CN Benzamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-57-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-58-7 CAPLUS
CN Methanesulfonamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-59-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[(2-pyrimidinylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-60-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-61-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-62-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-63-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-64-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methylphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-65-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methylphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-66-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-67-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-68-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-69-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-70-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-71-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-72-5 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(4-
pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-73-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(3-pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-75-8 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]methylamino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-76-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-77-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3,4-dimethoxyphenyl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-78-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-[1,1'-biphenyl]-4-ylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-79-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-80-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-82-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-84-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-85-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-86-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-87-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-89-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-04-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-06-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-07-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-08-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-09-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-10-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-fluoro-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-12-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-13-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-14-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-30-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(3-pyridinylmethoxy)phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-35-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(2-pyridinylmethoxy)phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 362601-36-3 CAPLUS
CN Acetamide, N-[4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl](2-phenylethyl)amino]butyl]- (9CI) (CA INDEX NAME)



RN 362601-37-4 CAPLUS
CN Methanesulfonamide, N-[4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl](2-phenylethyl)amino]butyl]- (9CI) (CA INDEX NAME)



RN 362601-38-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl](phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-39-6 CAPLUS
CN Carbamic acid, [4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl](2-phenylethyl)amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 362601-41-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-aminobutyl)(2-phenylethyl)amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-42-1 CAPLUS
CN Carbamic acid, [4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl][2-(2-methoxyphenyl)ethyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 362601-43-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-aminobutyl)[2-(2-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-44-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-aminobutyl)(3-phenylpropyl)amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-45-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-naphthalenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 362601-47-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[2-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-49-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[2-[3-(4-pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 362601-50-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-phenylpropyl)(trifluoromethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-51-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 362048-04-2
CMF C19 H17 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 362601-52-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-54-5 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 362601-55-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 362601-56-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 362601-58-9 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 362601-59-0 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(4-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 362601-60-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[methyl[2-(2-pyridinyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-61-4 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[3-(3-pyridinyl)propyl]amino]-(9CI) (CA INDEX NAME)



RN 362601-62-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(phenylmethyl)[2-(2-pyridinyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-64-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-phenylethyl)(3-pyridinylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-65-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-phenylethyl)(2-pyridinylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-67-0 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:709747 CAPLUS
DOCUMENT NUMBER: 135:257262
TITLE: Preparation of 2-[(heteroaryl)alkylamino]pyrimidones as GSK3β inhibitors
INVENTOR(S): Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1136491	A1	20010926	EP 2000-400806	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
EP 2000-400804 A 20000323
EP 2000-400805 A 20000323
EP 2000-400806 A 20000323
JP 2000-81938 A 20000323

OTHER SOURCE(S): MARPAT 135:257262

GI



I

AB The title compds. [I; R1 = H, alkyl; R2 = (un)substituted furyl, thienyl, pyrrolyl or imidazolyl; R3 = 2-, 3- or 4-pyridyl optionally substituted by alkyl, alkoxy or halogen; n = 1-5] which are used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents, brain and spinal trauma, and peripheral neuropathies, were prepared and formulated. Thus, reacting 2-(methylthio)-6-(pyridin-4-yl)pyrimidin-4(1H)-one (preparation given) with 3-furylmethylamine afforded I [R1 = H; R2 = 3-furyl; R3 = 4-pyridyl; n = 1]. The exemplified compds. I showed IC50's of 0.3-10 μM against GSK3β.

IT **361484-66-4P 361484-67-5P 361484-68-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-[(heteroaryl)alkylamino]pyrimidones as GSK3β inhibitors)

RN 361484-66-4 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(3-furanylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-67-5 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-68-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(2-thienyl)ethyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:709744 CAPLUS
DOCUMENT NUMBER: 135:257260
TITLE: Preparation of 2-[(indanylamino]pyrimidones and 2-[tetrahydronaphthalenylamino]pyrimidones as GSK3β inhibitors
INVENTOR(S): Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1136486	A1	20010926	EP 2000-400808	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001070725	A1	20010927	WO 2001-EP3636	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2000-400808 A 20000323

OTHER SOURCE(S): MARPAT 135:257260

GI



I

AB The title compds. [I; R1 = H, alkyl; R2 = H, alkyl, halo, etc.; R3 = 2-, 3- or 4-pyridyl group optionally substituted by alkyl, alkoxy or a halogen atom; n = 0-1; when n = 0 then m = 2 or 3, and when n = 1 then m = 1 or 2] which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents and brain and spinal trauma and peripheral neuropathies, were prepared and formulated. E.g., a 3-step synthesis of I [R1, R2 = H; R3 = 4-pyridyl; n, m = 1] which showed IC50 of 0.1 μM against GSK3β, was given.

IT **361458-95-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-[(indanylamino]pyrimidones and 2-[tetrahydronaphthalenylamino]pyrimidones as GSK3β inhibitors)

RN 361458-95-9 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(2,3-dihydro-1H-inden-2-yl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:709742 CAPLUS

DOCUMENT NUMBER: 135:257258

TITLE: Preparation of 2-(arylalkylamino)pyrimidones as GSK3β inhibitors

INVENTOR(S): Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak; Ando, Ryoichi; Watanabe, Kazutoshi

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.

SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

09/ 787,426

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1136484	A1	20010926	EP 2000-400804	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
EP 2000-400804 A 20000323
EP 2000-400805 A 20000323
EP 2000-400806 A 20000323
JP 2000-81938 A 20000323

OTHER SOURCE(S): MARPAT 135:257258
GI



I



II

AB The title compds. [I; R1 = unsubstituted naphth-1-yl, unsubstituted naphth-2-yl, substituted aryl; when n = 4-5 then R1 can represent unsubstituted Ph; R2 = H, alkyl; R3 = 2-, 3- or 4-pyridyl optionally substituted by alkyl, alkoxy group or a halogen atom] which are used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, were prepared and formulated. The compds. I were prepared by reacting the propionate R3COCH2COOR with the amidine R1(CH2)nNR2C(:NH)NH2 or by reacting the pyrimidinone II with amine R1(CH2)nNHR2. All exemplified compds. I such as I [R1 = 3,4-(MeO)2C6H3; R2 = H; R3 = 4-pyridyl; n = 1] showed IC50 of 0.01-10 μM against GSK3β.

IT **361542-10-1P 361542-11-2P 361542-12-3P**
361542-13-4P 361542-14-5P 361542-15-6P
361542-16-7P 361542-17-8P 361542-18-9P
361542-19-0P 361542-20-3P 361542-21-4P
361542-22-5P 361542-23-6P 361542-24-7P
361542-25-8P 361542-26-9P 361542-27-0P
361542-28-1P 361542-29-2P 361542-30-5P
361542-31-6P 361542-32-7P 361542-33-8P
361542-34-9P 361542-35-0P 361542-36-1P
361542-37-2P 361542-38-3P 361542-39-4P
361542-40-7P 361542-41-8P 361542-42-9P
361542-43-0P 361542-44-1P 361542-45-2P

361542-46-3P 361542-47-4P 361542-48-5P
361542-49-6P 361542-50-9P 361542-51-0P
361542-52-1P 361542-53-2P 361542-54-3P
361542-55-4P 361542-56-5P 361542-57-6P
361542-58-7P 361542-59-8P 361542-60-1P
361542-61-2P 361542-62-3P 361542-63-4P
361542-64-5P 361542-65-6P 361542-66-7P
361542-67-8P 361542-68-9P 361542-69-0P
361542-70-3P 361542-71-4P 361542-72-5P
361542-73-6P 361542-74-7P 361542-75-8P
361542-76-9P 361542-77-0P 361542-78-1P
361542-79-2P 361542-80-5P 361542-81-6P
361542-82-7P 361542-83-8P 361542-84-9P
361542-85-0P 361542-86-1P 361542-87-2P
361542-88-3P 361542-89-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(arylalkylamino)pyrimidones as GSK3β inhibitors)

RN 361542-10-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-11-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-12-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-13-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-

(9CI) (CA INDEX NAME)



RN 361542-14-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-15-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-16-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-17-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-18-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-bromophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-19-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,4-dichlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-20-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-21-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-22-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-nitrophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-23-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-aminophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-24-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-25-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-6-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-26-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-27-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methylphenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-28-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-
pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 361542-29-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-30-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-phenylbutyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-31-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-[1,1'-biphenyl]-4-ylethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-32-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-naphthalenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-33-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-34-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-35-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methylphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-36-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-37-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-fluorophenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-38-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-39-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-40-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]
amino]- (9CI) (CA INDEX NAME)



RN 361542-41-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-
pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-42-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-nitrophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-43-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-aminophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-44-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-45-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-46-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-47-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-48-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-49-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-aminophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-50-9 CAPLUS
CN Acetamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-51-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-52-1 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(2-pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-53-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(3-pyridinyl)propoxy]phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-54-3 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-55-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-aminophenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-56-5 CAPLUS
CN Benzamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-57-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-58-7 CAPLUS
CN Methanesulfonamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-59-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[(2-pyrimidinylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-60-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-61-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-62-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-63-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-64-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-65-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methylphenyl)propyl]amino]-6-(4-pyridinyl)-

(9CI) (CA INDEX NAME)



RN 361542-66-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-67-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-68-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-69-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-70-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-71-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-72-5 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(4-
pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-73-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(3-
pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-74-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[2-(2-pyridinyl)ethoxy]phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-75-8 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]methylamino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-76-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-77-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3,4-dimethoxyphenyl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-78-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-[1,1'-biphenyl]-4-ylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-79-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-80-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-81-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-82-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-83-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(3-pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-84-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-85-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-86-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-87-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-88-3 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[2-(2-pyridinyl)ethoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-89-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:709694 CAPLUS
DOCUMENT NUMBER: 135:262238
TITLE: Preparation of 2-(indolylalkylamino)pyrimidone derivatives as gsk3beta inhibitors
INVENTOR(S): Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1136099	A1	20010926	EP 2000-400805	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
EP 2000-400804 A 20000323
EP 2000-400805 A 20000323
EP 2000-400806 A 20000323
JP 2000-81938 A 20000323

OTHER SOURCE(S): MARPAT 135:262238
GI



I

AB A pyrimidone derivative represented by formula I or a salt thereof: wherein: R1 represents a hydrogen atom or a C1-6 alkyl group; R2 represents a hydrogen atom or a C1-6 alkyl group; R3 represents a 2, 3 or 4-pyridyl group optionally substituted by a C1-4 alkyl group, a C1-4 alkoxy group or a halogen atom; R4 represents a hydrogen atom, a C1-6 alkyl group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, methylenedioxy group, a nitro, a cyano, an amino, a C1-6 monoalkylamino group, C2-12 dialkylamino group, a C1-6 alkylcarbonylamino group, C6-10 arylcarbonylamino group, a Ph group or a benzyloxy group; and n represents 1 to 5. And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β (as glycogen synthase kinase 3β)such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents, brain and spinal cord trauma and peripheral neuropathies. A solution of 2-(methylthio)-6-pyridinyl-4-ylpyrimidin-4(1H)-one and different indolylalkylamines in amyl alc. were heated at 150° for 72 h to obtain 2-[indolylalkylamino]-6-pyridin-4-ylpyrimidin-4(1H)-one derivs. Inhibitory activity of the above derivs. against gsk3β was tested. A tablet contained a 2-(indolylalkylamino)pyrimidone derivative 30, crystalline cellulose 60, corn starch 100, lactose 200, and magnesium stearate 4 mg.

IT **362048-05-3P 362048-06-4P 362048-07-5P**
362048-08-6P 362048-09-7P 362048-10-0P
362048-11-1P 362048-12-2P 362048-13-3P
362048-14-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolylalkylaminopyrimidone derivs. as glycogen synthase kinase inhibitors)

RN 362048-05-3 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 362048-04-2
CMF C19 H17 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 362048-06-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-07-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-08-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-09-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-10-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-fluoro-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-11-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(7-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-12-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-13-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-14-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:531662 CAPLUS
DOCUMENT NUMBER: 133:120343
TITLE: Preparation of arylpyrimidinones and analogs as drugs
INVENTOR(S): Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: U.S., 92 pp., Cont.-in-part of U.S. Ser. No. 976,053, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 6096753	A	20000801	US 1997-985346	19971204
ZA 9710727	A	19980612	ZA 1997-10727	19971128
CN 1246857	A	20000308	CN 1997-181558	19971204
TW 520362	B	20030211	TW 1997-86118244	19971204
EP 1314731	A2	20030528	EP 2002-27704	19971204
EP 1314731	A3	20040102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, MK, AL				
EP 1314732	A2	20030528	EP 2002-27705	19971204
EP 1314732	A3	20040102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
ZA 9710911	A	19980605	ZA 1997-10911	19971205
US 6420385	B1	20020716	US 2000-504509	20000215
US 6410729	B1	20020625	US 2000-598740	20000621
US 2003069425	A1	20030410	US 2002-117552	20020403
US 6610698	B2	20030826		
US 2003073704	A1	20030417	US 2002-128271	20020423
US 6649604	B2	20031118		

PRIORITY APPLN. INFO.:	US 1996-32128P	P	19961205
	US 1997-50950P	P	19970613
	US 1997-976053	B2	19971121
	US 1997-976054	A	19971121
	EP 1997-954778	A3	19971204
	US 1997-984774	B1	19971204
	US 1997-985346	A3	19971204
	US 2000-504509	A3	20000215
	US 2000-598740	A3	20000621

OTHER SOURCE(S): MARPAT 133:120343

GI



I

AB Title compds. [e.g., I; Z = N or CR2; R1,R2 = R or Z1R; R = H, halo, alkoxy(carbonyl), amino(carbonyl or sulfonyl), etc.; R3 = Z1R; R4,R5 = (un)substituted (hetero)aryl; X = O, S, (un)substituted imino; Z1 = alkylene, heterocyclylene, (hetero)arylene, etc.] were prepared as agents for reduction of, e.g., TNF-α levels. Thus, 4-FC6H4CH2CO2Et was acylated by Et isonicotinate and the product cyclocondensed with (H2N)2CS to give, after N-methylation, I (R3 = Me, R4 = C6H4F-4, R5 = 4-pyridyl, X = O)(II; R1 = SH) which was aminated by 2-FC6H4CH(NH2)CH2CH2NH2 to give II [R1 = NHCH2CH2CH(NH2)C6H4F-2]. Data for biol. activity of I were given.

IT **208653-57-0P 208653-58-1P 208653-59-2P**
208653-60-5P 208653-61-6P 208653-62-7P
208654-83-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrimidinones and analogs as drugs)

RN 208653-57-0 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-58-1 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-59-2 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(1-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-60-5 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-61-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-

fluorophenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-62-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-(4-fluorophenyl)-6-(4-pyridinyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



RN 208654-83-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:227649 CAPLUS
DOCUMENT NUMBER: 132:265206
TITLE: Preparation of pyrimidones for treating diseases

caused by tau protein kinase 1 hyperactivity such as Alzheimer disease

INVENTOR(S): Watanabe, Kazutoshi; Ando, Ryoichi; Saito, Ken-ichi; Kawamoto, Rie; Shoda, Aya

PATENT ASSIGNEE(S): Mitsubishi Chemical Corporation, Japan

SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018758	A1	20000406	WO 1999-JP5224	19990924
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2345065	AA	20000406	CA 1999-2345065	19990924
AU 9957599	A1	20000417	AU 1999-57599	19990924
EP 1115721	A1	20010718	EP 1999-944815	19990924
EP 1115721	B1	20031210		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002525366	T2	20020813	JP 2000-572218	19990924
AT 256123	E	20031215	AT 1999-944815	19990924

PRIORITY APPLN. INFO.: JP 1998-271277 A 19980925
JP 1998-305266 A 19981027
WO 1999-JP5224 W 19990924

OTHER SOURCE(S): MARPAT 132:265206

GI



I

AB The title compds. [I; R1 = C1-18 alkyl, C3-18 alkenyl, C3-18 alkenyl, etc.; R2 = H, OH, C1-18 alkyl, etc.; R3 = (un)substituted pyridyl], useful for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as Alzheimer disease, were prepared and formulated. Thus, reacting Et 3-(4-pyridyl)-3-oxopropionate with 3-amidinopyridine.HCl in the presence of K2CO3 in EtOH afforded I [R1 = 3-pyridyl; R2 = H; R3 = 4-pyridyl] which showed IC50 of 2.3 μM against P-GS1 phosphorylation by bovine cerebral TPK1.

IT **54950-12-8P 54950-14-0P 263244-09-3P**
263244-10-6P 263244-16-2P 263244-25-3P
263244-26-4P 263244-27-5P 263244-30-0P
263244-31-1P 263244-32-2P 263244-34-4P
263244-35-5P 263244-36-6P 263244-37-7P

applicant's

263244-38-8P 263244-39-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidones for treating diseases caused by tau protein kinase 1 hyperactivity such as Alzheimer disease)

RN 54950-12-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-09-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-chloro-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-10-6 CAPLUS
CN Benzamide, N-[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 263244-16-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(diethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-25-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[methyl(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-26-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-27-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3,3-diphenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-30-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[methyl(2-methylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-31-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dipropylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-32-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-hydroxypropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-34-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(cyclohexylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-35-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-ethylphenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-36-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-butoxyphenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-37-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-bromophenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-38-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(phenylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-39-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-methoxyphenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:287423 CAPLUS
DOCUMENT NUMBER: 131:18977
TITLE: Synthesis of pyrimidines and azolopyrimidines as biodynamic agents
AUTHOR(S): Upadhyay, D. N.; Ram, Vishnu J.
CORPORATE SOURCE: Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, 226 001, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1999), 38B(2), 173-177
CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III

AB 5-Cyano-6-(4-pyridyl)-2-thiouracil (I) has been synthesized and used as a precursor for the synthesis of mono- and bicyclic pyrimidine derivs., e.g., II and III, to evaluate their antifungal and antileishmanial activities.

IT **226092-80-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(pyrimidines and azolopyrimidines as biodynamic agents)

RN 226092-80-4 CAPLUS

09/ 787,426

CN 5-Pyrimidinecarbonitrile, 2-hydrazino-1,4-dihydro-4-oxo-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:394334 CAPLUS
DOCUMENT NUMBER: 129:67791
TITLE: Preparation of 2-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidines and related compounds as drugs
INVENTOR(S): Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
PATENT ASSIGNEE(S): Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
SOURCE: PCT Int. Appl., 232 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824782	A2	19980611	WO 1997-US22390	19971204
WO 9824782	A3	19980827		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9710727	A	19980612	ZA 1997-10727	19971128
AU 9860120	A1	19980629	AU 1998-60120	19971204
AU 733877	B2	20010531		
EP 948497	A2	19991013	EP 1997-954778	19971204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9713850	A	20000229	BR 1997-13850	19971204
CN 1246858	A	20000308	CN 1997-181563	19971204
NZ 335997	A	20010831	NZ 1997-335997	19971204
JP 2002514195	T2	20020514	JP 1998-525850	19971204
TW 520362	B	20030211	TW 1997-86118244	19971204
EP 1314731	A2	20030528	EP 2002-27704	19971204
EP 1314731	A3	20040102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, MK, AL				
EP 1314732	A2	20030528	EP 2002-27705	19971204
EP 1314732	A3	20040102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, AL

ZA 9710911	A	19980605	ZA 1997-10911		19971205
MX 9905168	A	20000228	MX 1999-5168		19990603
US 6410729	B1	20020625	US 2000-598740		20000621
US 2003069425	A1	20030410	US 2002-117552		20020403
US 6610698	B2	20030826			

PRIORITY APPLN. INFO.:

US 1996-32128P	P	19961205
US 1997-50950P	P	19970613
US 1997-976054	A	19971121
EP 1997-954778	A3	19971204
US 1997-984774	B1	19971204
WO 1997-US22390	W	19971204
US 2000-598740	A3	20000621

OTHER SOURCE(S): MARPAT 129:67791

GI



I

AB Novel pyrimidines [I; R1, R2 = ZY, with a proviso; Z = bond, (un)substituted alk(en)yl, alkynyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl; etc; Y = H, halo, NO2, COR20, CNR5NR5R21, OR21, O2CR21, etc.; R5 = H, (un)substituted alk(en)yl, alkynyl, cycloalkyl, (hetero)aryl, etc.; R20 = (un)substituted alk(en)yl, alkynyl, aralkoxy, aralkylthio, aralkylsulfonyl, etc.; R21 = H, any of definitions for R20] and their pharmaceutically acceptable salts, effective for prophylaxis and treatment of diseases mediated by tumor necrosis factor α (TNF-α), IL-1β, IL-6 and/or IL-8 and other maladies, e.g., pain and diabetes, were prepared, e.g., by enamination of 2-(4-fluorophenyl)-1-(4-pyridinyl)ethanone (II) with (Me2N)2CHOMe and cyclocondensation of the resulting (dimethylamino)propenone with an amidine, guanidine or urea. I analogs, prodrugs , pharmaceutical compns., methods for prophylaxis and treatment of diseases or conditions involving inflammation, pain, diabetes, etc., and processes for making such compds. and their intermediates are also claimed. For example, heating a mixture of II with (Me2N)2CHOMe at 110° for 1.5 h under Ar gave 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridyl)-3-propen-1-one which was cyclocondensed with 4-pyridylamidine (prepared in situ from pyridylamidine-HCl and Na) by refluxing in EtOH to give a title compound I (R1 = R12 = 4-pyridinyl, R2 = H, R11 = 4-FC6H4). The latter in mice inhibited lipopolysaccharide-induced TNF-α release with IC50 ≤20 μM.

IT **208653-57-0P 208653-58-1P 208653-59-2P**
208653-60-5P 208653-61-6P 208653-62-7P
208654-83-5P 208936-36-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-substituted (fluorophenyl)(pyridyl)pyrimidines and related compds. as drugs)

RN 208653-57-0 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-58-1 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-59-2 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(1-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-60-5 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-61-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-

fluorophenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-62-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-(4-fluorophenyl)-6-(4-pyridinyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



RN 208654-83-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208936-36-1 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[methyl(2-phenylethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:394333 CAPLUS
DOCUMENT NUMBER: 129:54384
TITLE: Preparation of arylpyrimidinones and analogs as drugs
INVENTOR(S): Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.; Zablocki, Jeff A.
PATENT ASSIGNEE(S): Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.; Zablocki, Jeff A.
SOURCE: PCT Int. Appl., 298 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824780	A2	19980611	WO 1997-US22949	19971204
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9710727	A	19980612	ZA 1997-10727	19971128
AU 9855254	A1	19980629	AU 1998-55254	19971204
AU 735901	B2	20010719		
EP 948496	A2	19991013	EP 1997-951678	19971204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1246857	A	20000308	CN 1997-181558	19971204
BR 9713863	A	20000314	BR 1997-13863	19971204
NZ 335992	A	20010928	NZ 1997-335992	19971204
JP 2002514196	T2	20020514	JP 1998-525902	19971204
TW 520362	B	20030211	TW 1997-86118244	19971204
EP 1314731	A2	20030528	EP 2002-27704	19971204
EP 1314731	A3	20040102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, MK, AL				
EP 1314732	A2	20030528	EP 2002-27705	19971204
EP 1314732	A3	20040102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
ZA 9710911	A	19980605	ZA 1997-10911	19971205
MX 9905158	A	20000331	MX 1999-5158	19990603
US 6410729	B1	20020625	US 2000-598740	20000621
US 2003069425	A1	20030410	US 2002-117552	20020403
US 6610698	B2	20030826		

PRIORITY APPLN. INFO.:

US	1996-32128P	P	19961205
US	1997-50950P	P	19970613
US	1997-976053	A	19971121
US	1997-976054	A	19971121
EP	1997-954778	A3	19971204
US	1997-984774	B1	19971204
WO	1997-US22949	W	19971204
US	2000-598740	A3	20000621

OTHER SOURCE(S): MARPAT 129:54384

GI



I

AB Title compds. [e.g., I; Z = N or CR2; R1,R2 = R or Z1R; R = H, halo, alkoxy(carbonyl), amino(carbonyl or sulfonyl), etc.; R3 = Z1R; R4,R5 = (un)substituted (hetero)aryl; X = O, S, (un)substituted imino; Z1 = alkylene, heterocyclylene, (hetero)arylene, etc.] were prepared as agents for reduction of, e.g., TNF-α levels. Thus, 4-FC6H4CH2CO2Et was acylated by Et isonicotinate and the product cyclocondensed with (H2N)2CS to give, after N-methylation, I (R3 = Me, R4 = C6H4F-4, R5 = 4-pyridyl, X = O)(II; R1 = SH) which was aminated by 2-FC6H4CH(NH2)CH2CH2NH2 to give II [R1 = NHCH2CH2CH(NH2)C6H4F-2]. Data for biol. activity of I were given.

IT **208653-57-0P 208653-58-1P 208653-59-2P 208653-60-5P 208653-61-6P 208653-62-7P 208654-83-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrimidinones and analogs as drugs)

RN 208653-57-0 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-58-1 CAPLUS

CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-59-2 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(1-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-60-5 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-61-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-62-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-(4-fluorophenyl)-6-(4-pyridinyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



RN 208654-83-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1985:596051 CAPLUS
DOCUMENT NUMBER: 103:196051
TITLE: Pyrimidinones. 1. 2-Amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-inducing antiviral agents
AUTHOR(S): Skulnick, Harvey I.; Weed, Sheldon D.; Eidson, Emerson E.; Renis, Harold E.; Stringfellow, Dale A.; Wierenga, Wendell
CORPORATE SOURCE: Cancer Virus Res., Upjohn Co., Kalamazoo, MI, 49001,

09/ 787,426

	USA
SOURCE:	Journal of Medicinal Chemistry (1985), 28(12), 1864-9 CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 103:196051

GI



I

excluded

AB Title compds. I [R = Ph, halo-, alkoxy-, hydroxy-, nitro-, (trifluoromethyl)-, alkyl-, amino-, cyano-, carboxy-, or benzyloxyphenyl, naphthyl, furyl, pyridyl, pyrazinyl, quinolyl; R1 = Cl, Br, iodo] (about 110 compds.), which were prepared, exhibited virucidal activity. I (R = Ph, R1 = H) was halogenated by N-chlorosuccinimide in HOAc to give I (R = Ph, R1 = Cl).

IT **54950-12-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(halogenation of)

RN 54950-12-8 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT **98305-54-5P 98305-55-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and virucidal activity of)

RN 98305-54-5 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 98305-55-6 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-5-iodo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1985:471335 CAPLUS
DOCUMENT NUMBER: 103:71335
TITLE: Triazolopyrimidine derivatives and their use as cardiac stimulants
INVENTOR(S): Barthelemy, Gerard; Hallot, Andre; Vallat, Jean Noel
PATENT ASSIGNEE(S): SANOFI, Fr.
SOURCE: Fr. Demande, 13 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2549834	A1	19850201	FR 1983-12443	19830725
FR 2549834	B1	19851018		
IL 72330	A1	19870227	IL 1984-72330	19840706
US 4581358	A	19860408	US 1984-628916	19840709
ZA 8405301	A	19850227	ZA 1984-5301	19840710
AU 8430791	A1	19850131	AU 1984-30791	19840718
AU 562596	B2	19870611		
DK 8403605	A	19850126	DK 1984-3605	19840723
ES 534550	A1	19850501	ES 1984-534550	19840723
CS 248718	B2	19870212	CS 1984-5626	19840723
NO 8403003	A	19850128	NO 1984-3003	19840724
EP 136198	A1	19850403	EP 1984-401551	19840724
EP 136198	B1	19880210		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
CA 1226284	A1	19870901	CA 1984-459573	19840724
AT 32462	E	19880215	AT 1984-401551	19840724
FI 8402966	A	19850126	FI 1984-2966	19840725
JP 60051190	A2	19850322	JP 1984-155127	19840725
HU 34753	O	19850429	HU 1984-2861	19840725
HU 190653	B	19861028		
DD 222593	A5	19850522	DD 1984-265646	19840725
SU 1347865	A3	19871023	SU 1984-3767330	19840725

PRIORITY APPLN. INFO.: FR 1983-12443 19830725
EP 1984-401551 19840724

OTHER SOURCE(S): CASREACT 103:71335
GI



I



II



III

AB Triazolopyrimidinones I and II (R = alkyl; R1 = pyridyl, alkyl-, alkoxy-, hydroxy-, or cyanopyridyl; R2 = H, alkyl, unsatd. aliphatic group), which were prepared, showed cardiovascular activity. Hydrazinopyrimidinone III was heated with MeC(OEt)3 in BuOH to give I (R = Me, R1 = 3-pyridyl, R2 = H).

IT **97545-28-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with ortho esters)

RN 97545-28-3 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-(4-pyridinyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



L3 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1976:44112 CAPLUS
DOCUMENT NUMBER: 84:44112
TITLE: 4-Hydroxy-pyridylpyrimidine derivatives
INVENTOR(S): Tani, Hidero; Nakamura, Koji; Mori, Yasuhiro; Yokoo, Nobuo; Kyotani, Yoshinori; Wada, Yasushi
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49035631	B4	19740925	JP 1970-127611	19701228

PRIORITY APPLN. INFO.: JP 1970-127611 19701228
GI For diagram(s), see printed CA Issue.
AB Seven pyrimidinols (I, R = 2-, 3-, 4-pyridyl, R1 = H, Me, or R12N = morpholino), useful as antiinflammatory agents (no data), were prepared from

the corresponding pyridylcarbonylacetic acid ester and guanidine derivs. [R12NC(:NH)NH2]. E.g., 54.9 g nicotinoylacetic acid Me ester in 53 g EtOAc was refluxed with EtO Na (obtained from 11.5 g Na and 200 ml EtOH) for 10 hr and the reaction mixture was adjusted with H2SO4 to pH 7 to give 24.95 g nicotinoylacetic acid Et ester, which (18.1 g) was refluxed 5 hr with 12.6 g H2NC(:NH)NH2 carbonate in 60 ml EtOH to give I (R = 3-pyridyl, R1 = H).

IT **54950-12-8P 54950-14-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 54950-12-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:410129 CAPLUS
DOCUMENT NUMBER: 83:10129
TITLE: 2-(Substituted)-4-hydroxy-6-pyridylpyrimidine derivatives
INVENTOR(S): Tani, Hidero; Nakamura, Koji; Mori, Yasuhiro; Yokoo, Nobuo; Kyotani, Yoshinori; Wada, Yasushi
PATENT ASSIGNEE(S): Mori, Hiroshi
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49035634	B4	19740925	JP 1970-128203	19701230

PRIORITY APPLN. INFO.: JP 1970-128203 19701230
GI For diagram(s), see printed CA Issue.
AB Seven 2-amino-6-pyridyl-4-pyrimidinols (I, R = H2, Me, or R2N = morpholino; R1 = 2-, 3-, or 4-pyridyl), useful as antiinflammatory agents, were prepared from the 2-(methylthio) derivs. and the appropriate amines. E.g., 3.0 g 2-(methylthio)-6-(4-pyridyl)-4-pyrimidinol, obtained from reaction of H2NC(:S)NH2 with Et isonicotinoylacetate and subsequent

methylation, was treated with 260 mg Me2NH in BuOH at 150° for 2 hr to give 76.5% I (R = Me, R1 = 4-pyridyl).

IT **54950-12-8P 54950-14-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 54950-12-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:410127 CAPLUS
DOCUMENT NUMBER: 83:10127
TITLE: 5-Nitro-6-pyridylprimidine derivatives
INVENTOR(S): Tani, Hidero; Nakamura, Koji; Yokoo, Nobuo; Kyotani, Yoshinori; Akaishi, Keisuke
PATENT ASSIGNEE(S): Mori, Hiroshi
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49035633	B4	19740925	JP 1970-128199	19701230

PRIORITY APPLN. INFO.: JP 1970-128199 19701230
GI For diagram(s), see printed CA Issue.
AB Three 5-nitro-2-amino-4-(4-pyridyl)pyrimidines (R = H, Me; R1 = OH, NH2), useful as antiinflammatory agents, were prepared by nitration of the corresponding II. Thus, 15 g II (R = Me, R1 = NH2) was treated with a mixture of 10 ml fuming HNO3 and 50 ml H2SO4 for 1 hr and the mixture was treated with 28% NH3-H2O to give 8.08 g I (R = Me, R1 = NH2).

IT **54950-14-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(nitration of)

RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT **55361-89-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55361-89-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-5-nitro-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:171028 CAPLUS
DOCUMENT NUMBER: 82:171028
TITLE: 2,4,5-Trisubstituted-6-pyridylpyrimidine derivatives
INVENTOR(S): Tani, Hideo; Nakamura, Koji; Yokoo, Nobuo; Kyoya, Yoshinori; Akashi, Keisuke
PATENT ASSIGNEE(S): Mori, Hiroshi
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49036719	B4	19741002	JP 1970-128201	19701230

PRIORITY APPLN. INFO.: JP 1970-128201 19701230
GI For diagram(s), see printed CA Issue.
AB Pyridylpyrimidinols [I, R = 1-piperidinylmethyl (II), morpholinomethyl], useful as antiinflammatory agents (no data), were prepared by reacting I (R = H) with RH and formalin. E.g., 650 mg I (R = H) was refluxed with 0.036 ml HOAc, 306 mg piperidine, 0.375 ml formalin and 6 ml EtOH for 45 min, the mixture allowed to stand for 2.5 hr, 0.1 ml formalin added, and the mixture again refluxed for 1.5 hr to give 44 mg II. II·HCl was also prepared
IT **55362-49-7P 55362-50-0P 55362-51-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55362-49-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-5-(1-piperidinylmethyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 55362-50-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-5-(1-piperidinylmethyl)-6-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 55362-51-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-5-(4-morpholinylmethyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT **54950-14-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with amines and formaldehyde)
RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:140173 CAPLUS
DOCUMENT NUMBER: 82:140173
TITLE: 2,4,6-Trisubstituted pyrimidines
INVENTOR(S): Tani, Hideo; Nakamura, Koji; Mori, Shizuhiro; Yokoo, Nobuo; Kyotani, Yoshitoku; Wada, Yasushi
PATENT ASSIGNEE(S): Kowa Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 12 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49021148	B4	19740530	JP 1970-127609	19701228

PRIORITY APPLN. INFO.: JP 1970-127609 19701228
GI For diagram(s), see printed CA Issue.
AB Sixty-three antiinflammatory (no data) pyrimidines (R = 4-pyridyl, Ph, etc., R1 = NH2, NMe2, NEt2, morpholino, NHPr, piperidino, OMe, etc., R2 = NMe2, OCH2CH2NMe2, NEt2, morpholino, NHCH2CH:CH2, NHCH2CH2OH, etc.) were prepared by reacting I (R1 = SO2Me or Cl) with the appropriate amine or alc. E.g., I (R = NH2, R1 = SO2Me, R2 = 4-pyridyl) (0.016 mole) was refluxed 1 hr with 30 ml MeOH containing 0.03 mole Na to give 80% I (R = NH2, R1 = OMe, R2 = 4-pyridyl).
IT **54993-99-6P 54994-00-2P 54994-01-3P 54994-02-4P 54994-03-5P 54994-04-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 54993-99-6 CAPLUS
CN 2-Pyrimidinamine, 4-methoxy-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-00-2 CAPLUS
CN 2-Pyrimidinamine, 4-ethoxy-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-01-3 CAPLUS
CN 2-Pyrimidinamine, 4-butoxy-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-02-4 CAPLUS
CN 2-Pyrimidinamine, 4-(phenylmethoxy)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-03-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(dimethylamino)ethoxy]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-04-6 CAPLUS
CN 2-Pyrimidinamine, 4-[3-(diethylamino)propoxy]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:14:26 ON 27 MAY 2004)

FILE 'REGISTRY' ENTERED AT 14:14:35 ON 27 MAY 2004
L1 STRUCTURE UPLOADED
L2 161 S L1 FUL

FILE 'CAPLUS' ENTERED AT 14:15:03 ON 27 MAY 2004
L3 20 S L2

=> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL

09/ 787,426

	ENTRY	SESSION
FULL ESTIMATED COST	96.01	251.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.86	-13.86

STN INTERNATIONAL LOGOFF AT 14:16:26 ON 27 MAY 2004